ASH 2020 | Venetoclax, lenalidomide and rituximab in R/R MCL
Mats Jerkeman, MD, PhD, Skane University Hospital, Lund, Sweden, shares the preliminary results of the Phase Ib/II trial (NCT03505944) investigating the combination of venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma (MCL). By introducing an intermediate dose of venetoclax and lenalidomide, the Phase I study showed a good safety profile. The ongoing Phase II trial shows that around half of the patients had disease progression, whereas half of the patients responded well and achieved molecular remission. Additionally, these results suggest treatment can be stopped in patients that have achieved molecular remission, however, follow-up is still ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research support: Janssen, Celgene, Abbvie, Roche, Gilead
Honoraria: Celgene, Gilead, Roche, Incyte
